Publication | Open Access

A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit

HlaHistocompatibilityOncologyMedicineProstate Cancer PatientsImmunologyPathologyClinical BenefitHla TypingProstatic DiseaseImmunotherapyMolecular DiagnosticsImmune-related Gene PolymorphismPilot Study